直立性低血压的新进展
本文为叙述性综述,概述近年老老年人直立性低血压(OH)诊断、治疗与预后的新证据。诊断标准修订纳入了血压下降持续时间及初始型、延迟型和伴高血压OH等分类;非药物治疗仍为一线,综合老年评估(CGA)似可降低OH发生率;米多君是英国唯一获批药物。
要点
- 诊断标准修订纳入血压下降持续时间及初始型、延迟型、伴高血压OH分类
- 非药物治疗仍为一线,CGA似可降低OH发生率
- 米多君为英国唯一获批药物,氟氢可的松可先于米多君考虑
核心结论
- OH在老年人中仍常见,新诊断标准解决了部分既往不确定性,但停用降压药证据相互矛盾。
- 非药物治疗仍为一线,CGA似可降低OH发生率,米多君是英国唯一获批药物。
- 与OH相关的死亡率增加在老年人中不那么明显。
研究设计与样本
- 叙述性综述,回顾近期研究、新兴治疗及相关监管更新。
- 综述未报告系统检索范围与样本量。
主要发现
- OH诊断标准修订包括血压下降持续时间、初始型和延迟型OH及伴高血压OH的具体标准。
- 非药物治疗仍为一线选择,CGA似可带来较低的OH发生率。
- 关于停用致病药物的近期证据不一致。
- 米多君近期成为英国唯一获批用于OH的药物。
- 阿托莫西汀和屈昔多巴等新兴治疗需进一步评估;其他许多药物缺乏高质量证据支持。
关键数值与推荐
- 米多君是英国唯一获批的OH治疗药物。
- 氟氢可的松可在米多君之前考虑。
- 屈昔多巴等药物未来可能应用增多,但需进一步评估。
临床怎么用
- 老年OH患者应首选非药物治疗,并可结合CGA管理。
- 停用致病药物需权衡,因近期证据不一致。
- 药物治疗可考虑氟氢可的松先于米多君,米多君为英国唯一获批药物。
局限性
- 为叙述性综述,未报告系统检索策略与纳入研究数量。
- 部分证据来自较年轻慢性神经疾病人群,对老年人的适用性不确定。
- 停用致病药物的证据不一致,新兴治疗仍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: orthostatic hypotension (OH) is a common disabling condition associated with increased morbidity and mortality. Much of the evidence available is derived from younger populations with chronic neurological disease leading to uncertainty for the diagnosis and management of older people. OBJECTIVE: to provide an overview of recent and emerging evidence for the diagnosis, management and prognosis of OH in older persons. METHODS: a narrative review of recent studies, emerging therapies and relevant regulatory updates. FINDINGS: revisions to the diagnostic criteria for OH include the duration of the blood pressure drop, specific criteria for initial and delayed OH and OH with hypertension. Non-drug therapies remain the first-line treatment option and Comprehensive Geriatric Assessment appears to result in lower rates of OH. Recent evidence concerning withdrawal of causative medication is inconsistent. Midodrine has recently become the only licenced medication for OH in the UK. Other emerging treatments include atomoxetine and droxidopa but these require further evaluation. Many other agents may be used but are not supported by high-quality evidence. The increase in mortality associated with OH is less apparent in older people. SUMMARY: OH remains common in older people, the new diagnostic criteria address some of the previous uncertainty but evidence concerning withdrawal of antihypertensives is conflicting. Midodrine is now the only licenced medication for OH in the UK, but non-drug therapies remain first line and fludrocortisone may be considered before midodrine. We may see other agents such as droxidopa becoming increasingly used over the coming years.
引用
- Frith J, Parry SW. New Horizons in orthostatic hypotension. Age Ageing. 2017. PMID: 27864240. doi:10.1093/ageing/afw211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。